CELH Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Revenue: $818 million, up 11% year-over-year.

Brand Performance:

CELSIUS: Net sales down 12% year-over-year; retail sales in tracked channels down 2%.

Alani Nu: Net sales of $364 million, up 21% year-over-year; retail sales grew 56%.

Rockstar: Net sales of $66 million, post-integration.

Gross Margin: Approximately 48%, consistent with Q1.

Adjusted EBITDA: $184 million (22.5% of revenue), down from $210 million year-over-year.

SG&A Expenses: $238 million (29% of revenue), down from 32% a year ago.

2Strategic Updates and Business Highlights

Completed integration of Rockstar within the expected timeline.

Focused on SKU optimization for CELSIUS, leading to improved distribution efficiency.

Alani Nu achieved over $1 billion in retail sales in tracked channels.

Strong innovation pipeline with new flavors and limited-time offers (LTOs) planned for the second half of 2026.

International expansion plans are underway, targeting 15% of revenue from international markets over the next five years.

3Forward Guidance and Outlook

Anticipate Q3 performance for CELSIUS to mirror Q2, with expectations of returning to growth in Q4.

Continued momentum for Alani Nu expected, with significant LTOs planned for the fall.

Focus on improving service quality and distribution efficiency in the second half of 2026.

Strong plans for 2027, including new marketing campaigns and expanded athlete partnerships.

4Bad News, Challenges, or Points of Concern

CELSIUS brand faced a decline in net sales and retail performance due to SKU rationalization and limited innovation.

Challenges in achieving expected shelf space gains and delays in retail allocations for new product placements.

Increased trade and promotional investments impacted net revenue.

Competitive pressures from new entrants in the energy drink market and potential risks from ongoing commodity inflation.

5Notable Q&A Insights

Management acknowledged that SKU rationalization for CELSIUS may have been too aggressive and indicated a need for a more balanced approach moving forward.

Confidence in CELSIUS's recovery is based on strong brand health metrics and planned innovations for 2027.

Alani Nu's performance is expected to face tough comparisons in Q4 due to prior year inventory builds, but new innovations are anticipated to drive growth.

International markets are seen as a significant growth opportunity, with plans to introduce Alani Nu in select regions in 2027. Overall, while CELH is navigating challenges with the CELSIUS brand, the company remains optimistic about its strategic initiatives and growth potential, particularly with Alani Nu and international expansion.